{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:14:11Z","timestamp":1785255251214,"version":"3.55.0"},"reference-count":42,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.2060","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:07:23Z","timestamp":1758528443000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Potential of doxofylline in the treatment of chronic obstructive airway diseases (Review)"],"prefix":"10.3892","volume":"23","author":[{"given":"Serghei","family":"Covantsev","sequence":"first","affiliation":[{"name":"Federal State Autonomous Institution National Medical Research Centre \u2018Treatment and Rehabilitation Centre\u2019 of the Ministry of Health of The Russian Federation, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Poparcea","sequence":"additional","affiliation":[{"name":"Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy Nicolae Testemitanu, Chisinau MD\u20112004, Republic of Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bumbu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Botkin Hospital, Moscow 125284, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, Iasi 700115, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Georgakopoulou","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Laiko General Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Spandidos","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion 71003, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Corlateanu","sequence":"additional","affiliation":[{"name":"Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy Nicolae Testemitanu, Chisinau MD\u20112004, Republic of Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"100164","key":"key20251014125421_b1-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"issue":"297","key":"key20251014125421_b2-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-17686-9","article-title":"Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis","volume":"24","author":"Al Wachami","year":"2024","journal-title":"BMC Public Health"},{"key":"key20251014125421_b3-BR-23-5-02060"},{"key":"key20251014125421_b4-BR-23-5-02060"},{"key":"key20251014125421_b5-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.coi.2020.10.006","article-title":"Asthma-chronic obstructive pulmonary disease overlap syndrome","volume":"66","author":"Mart","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"key20251014125421_b6-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.tips.2010.04.009","article-title":"New therapies for asthma: Is there any progress?","volume":"31","author":"Barnes","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"key20251014125421_b7-BR-23-5-02060","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/acsmedchemlett.2c00166","article-title":"An unexpected deuterium-induced metabolic switch in doxofylline","volume":"13","author":"Aprile","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"key20251014125421_b8-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pupt.2010.04.002","article-title":"Doxofylline: A \u2018novofylline\u2019","volume":"23","author":"Page","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"issue":"2400103","key":"key20251014125421_b9-BR-23-5-02060","article-title":"Doxofylline: Advancing and empowering equitable asthma and COPD management beyond tradition","volume":"7","author":"Cazzola","year":"2024","journal-title":"Adv Therap"},{"key":"key20251014125421_b10-BR-23-5-02060","first-page":"3487","article-title":"Doxofylline is not just another theophylline! Int J Chron Obstruct Pulmon","volume":"12","author":"Matera","year":"2017","journal-title":"Dis"},{"key":"key20251014125421_b11-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pupt.2011.10.007","article-title":"The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism","volume":"25","author":"van Mastbergen","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"e00829","key":"key20251014125421_b12-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00829","article-title":"Xanthine scaffold: Scope and potential in drug development","volume":"4","author":"Singh","year":"2018","journal-title":"Heliyon"},{"issue":"25","key":"key20251014125421_b13-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1186\/s40248-019-0189-0","article-title":"Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis","volume":"14","author":"Rogliani","year":"2019","journal-title":"Multidiscip Respir Med"},{"key":"key20251014125421_b14-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"key20251014125421_b15-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/CIRCRESAHA.107.154229","article-title":"Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3","volume":"101","author":"Surapisitchat","year":"2007","journal-title":"Circ Res"},{"key":"key20251014125421_b16-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pupt.2012.05.007","article-title":"cAMP regulation of airway smooth muscle function","volume":"26","author":"Billington","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"key20251014125421_b17-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1517\/14656560903200667","article-title":"Doxofylline: A promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease","volume":"10","author":"Shukla","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"180010","key":"key20251014125421_b18-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0010-2018","article-title":"Efficacy and safety profile of xanthines in COPD: A network meta-analysis","volume":"27","author":"Cazzola","year":"2018","journal-title":"Eur Respir Rev"},{"key":"key20251014125421_b19-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/164_2016_64","article-title":"\u03b22 agonists","volume":"237","author":"Billington","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"e388","key":"key20251014125421_b20-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2022.90","article-title":"Inhaled bronchodilators and corticosteroids in the management of bronchiolitis obliterans due to allogenic hematopoietic stem cell transplantation","volume":"37","author":"Georgakopoulou","year":"2022","journal-title":"Oman Med J"},{"issue":"220267","key":"key20251014125421_b21-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0267-2022","article-title":"Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022","volume":"19","author":"Stolz","year":"2023","journal-title":"Breathe (Sheff)"},{"issue":"26","key":"key20251014125421_b22-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.3892\/mi.2022.51","article-title":"Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review)","volume":"2","author":"Garmpi","year":"2022","journal-title":"Med Int (Lond)"},{"issue":"19","key":"key20251014125421_b23-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.3390\/epigenomes3030019","article-title":"Targeting HDAC complexes in asthma and COPD","volume":"3","author":"Zwinderman","year":"2019","journal-title":"Epigenomes"},{"key":"key20251014125421_b24-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pupt.2014.01.001","article-title":"Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse","volume":"27","author":"Riffo-Vasquez","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"key20251014125421_b25-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.12139","article-title":"Protein kinase C and its inhibitors in the regulation of inflammation: Inducible nitric oxide synthase as an example","volume":"114","author":"Lepp\u00e4nen","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20251014125421_b26-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/21691401.2020.1730391","article-title":"The protective effect of doxofylline against lipopolysaccharides (LPS)-induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells","volume":"48","author":"Jiao","year":"2020","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"key20251014125421_b27-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2017.10.008","article-title":"Steroid sparing effects of doxofylline","volume":"48","author":"Riffo-Vasquez","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"key20251014125421_b28-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/jmr.2549","article-title":"Identifying the antiasthmatic target of doxofylline using immobilized \u03b22 -adrenoceptor based high-performance affinity chromatography and site-directed molecular docking","volume":"29","author":"Zhang","year":"2016","journal-title":"J Mol Recognit"},{"key":"key20251014125421_b29-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pupt.2018.09.007","article-title":"Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2)","volume":"53","author":"Calzetta","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"key20251014125421_b30-BR-23-5-02060"},{"key":"key20251014125421_b31-BR-23-5-02060"},{"key":"key20251014125421_b32-BR-23-5-02060","first-page":"585","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic respiratory diseases, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key20251014125421_b33-BR-23-5-02060"},{"key":"key20251014125421_b34-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.7860\/JCDR\/2012\/4697.2643","article-title":"Doxofylline and theophylline: A comparative clinical study","volume":"6","author":"Akram","year":"2012","journal-title":"J Clin Diagn Res"},{"key":"key20251014125421_b35-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2018.04.010","article-title":"Impact of doxofylline in COPD: A pairwise meta-analysis","volume":"51","author":"Cazzola","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"issue":"105904","key":"key20251014125421_b36-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105904","article-title":"The effect of doxofylline in asthma and COPD","volume":"164","author":"Cazzola","year":"2020","journal-title":"Respir Med"},{"key":"key20251014125421_b37-BR-23-5-02060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.18203\/2319-2003.ijbcp20181163","article-title":"Evaluation of efficacy and safety of doxofylline 800mg sustained release tablet in treatment of patients with COPD: An open label, prospective and RCT","volume":"7","author":"Khandelwal","year":"2018","journal-title":"Int J Basic Clin Pharmacol"},{"key":"key20251014125421_b38-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000448625","article-title":"Predicting health-related quality of life in patients with chronic obstructive pulmonary disease: The impact of age","volume":"92","author":"Corlateanu","year":"2016","journal-title":"Respiration"},{"key":"key20251014125421_b39-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"45","DOI":"10.15326\/jcopdf.4.1.2016.0126","article-title":"GOLD stage and treatment in COPD: A 500 patient point prevalence study","volume":"4","author":"Safka","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"key":"key20251014125421_b40-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2147\/COPD.S319220","article-title":"Bronchodilator response in patients with COPD, Asthma-COPD-Overlap (ACO) and asthma, evaluated by plethysmographic and spirometric z-score target parameters","volume":"16","author":"Kraemer","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"101883","key":"key20251014125421_b41-BR-23-5-02060","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101883","article-title":"A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: the LESDA study","volume":"60","author":"Calzetta","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"key20251014125421_b42-BR-23-5-02060","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1378\/chest.96.4.772","article-title":"Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure","volume":"96","author":"Poggi","year":"1989","journal-title":"Chest"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T09:54:27Z","timestamp":1760435667000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.2060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.2060","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}